1 Min Read
March 23 (Reuters) - Alligator Bioscience AB:
* Announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013
Source text for Eikon:
Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.